Dr Will Herrington
|Tel||+44 (0)1865 743926|
Senior Clinical Research Fellow, Renal Studies Group, Clinical Trial Service Unit and Epidemiological Studies Unit
Will Herrington studied medicine at University of Cambridge and University College London (1997-2003) and has practised in nephrology since 2006. He was appointed an Honorary Consultant Nephrologist at Oxford Kidney Unit in 2014. He joined the Renal Studies Group at CTSU in 2010 as a Clinical Research Fellow and worked on SHARP and 3C, two landmark trials in nephrology. He was awarded an MD from the University of Cambridge in 2013 for his thesis entitled ‘The effects of lowering LDL cholesterol on stroke in chronic kidney disease’ and retains a key interest in the safety and efficacy of lowering LDL cholesterol on both renal and vascular outcomes in people with chronic kidney disease.
His current research also focuses on understanding the key determinants of developing kidney disease and cardiovascular disease; the use of routine healthcare data and mobile technology for streamlined randomized trials and large-scale renal epidemiology; the effects of blood pressure, diabetes and adiposity on cause-specific mortality in the Mexico City Prospective Study; and validation of biochemical methods for use in renal epidemiology. He is module co-lead for the Record Linkage and Bioinformatics module in the department’s MSc in Global Health Science, is a subject editor for the Clinical Kidney Journal, an adviser to the Kidney Health Initiative and Clinical Trials Transformation Initiative and Scientific Co-ordinator for the KDIGO Controversies Conference on Challenges in the Conduct of Clinical Trials in Nephrology.
Association between diabetes and cause-specific mortality in rural and urban China
Bragg F. et al, (2017), JAMA
Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection.
Mafham MM. et al, (2017), Nephrol Dial Transplant
Are statins useful in patients with advanced chronic kidney disease? - Authors' reply.
Herrington WG. et al, (2016), Lancet Diabetes Endocrinol, 4, 971 - 972
Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP).
Staplin N. et al, (2016), Am J Kidney Dis, 68, 371 - 380
Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials
Herrington W. et al, (2016), The Lancet Diabetes and Endocrinology